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Objective. To determine the prognostic value of pulmonary function test (PFT) trends at 1 and 2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc).
Methods. The prognostic significance of PFT trends at 1 year (n 5 162) and 2 years (n 5 140) was examined against 15-year survival in patients with SScassociated ILD. PFT trends, expressed as continuous change and as categorical change in separate analyses, were examined against mortality in univariate and multivariate models. SSc-associated ILD was defined at presentation as either limited lung fibrosis or extensive lung fibrosis, using the United Kingdom Raynaud's and Scleroderma Association severity staging system.
Results. One-year PFT trends were predictive of mortality only in patients with extensive lung fibrosis: categorical change in the forced vital capacity (FVC), alone or in combination with categorical change in the diffusing capacity for carbon monoxide (DLCO), had greater prognostic significance than continuous change in the FVC or trends in other PFT variables. Taking into account both prognostic value and sensitivity to change, the optimal definition of progression for trial purposes was an FVC and DLCO composite end point, consisting of either an FVC decline from baseline of ‡10% or an FVC decline of 5-9% in association with a DLCO decline of ‡15%. At 2 years, gas transfer trends had the greatest prognostic significance, in the whole cohort and in those with limited lung fibrosis. However, in patients with extensive lung fibrosis, the above-defined FVC and DLCO composite end point was the strongest prognostic determinant. Larger changes in the FVC:DLCO ratio than in the carbon monoxide transfer coefficient were required to achieve prognostic significance.
Conclusion. Based on linkages to long-term outcomes, these findings provide support for use of routine spirometry and gas transfer monitoring in patients with SSc-associated ILD, with further evaluation of a composite FVC and DLCO end point warranted for trial purposes.
At presentation, prognostic evaluation is similar in systemic sclerosis (SSc)-associated interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). In both diseases, mortality is linked to disease severity at baseline, variably quantified using pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) (1) (2) (3) (4) (5) . However, prognostic evaluation in IPF is more nuanced than in SSc-associated ILD in one important regard. It has been demonstrated in a large number of IPF studies that serial decline in the forced vital capacity (FVC) over 6-12 months is a powerful predictor of mortality (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Based on these findings, the FVC is now universally regarded as central to routine monitoring in IPF (16) . Furthermore, links between short-term FVC change and mortality provide support for the choice of FVC as the primary end point in current trials assessing patients with IPF (17, 18) .
In SSc-associated ILD, the data currently existing are limited with regard to the relationship between shortterm pulmonary function trends and intermediate-term to long-term survival (19) . Although conventional pulmonary function thresholds have been explored for application in clinical practice (19) , little is known about the optimal measure for use in clinical trials. Monitoring strategies in clinical practice and the choice of FVC as a primary end point in treatment trials in patients with SSc-associated ILD have largely been based on the findings from IPF studies. However, important caveats in extrapolating from the IPF data include the fact that SSc-associated ILD is less progressive than IPF (thus potentially influencing the optimal expression of FVC trends in prognostic evaluation), and many patients with SSc-associated ILD have a disproportionate frequency of pulmonary vasculopathy (20) .
In the present study, we evaluated the relationship of PFT trends at 1 year and at 2 years against 15-year survival in a large cohort of patients with SSc-associated ILD for whom definitive follow-up information was available. Our findings have implications both for routine clinical monitoring and for future study design in the management of SSc-associated ILD.
PATIENTS AND METHODS
Patients. Data for 215 patients with SSc-associated ILD from a previously published cohort (in which baseline variables were examined against outcome) (3) were reviewed. Exclusion criteria were 1) death within 9 months of follow-up (n 5 15), and 2) no serial lung function measurements within the first 12 months (because of a shared model of care [n 5 38]). The remaining 162 patients made up the study population. In order to exclude the possibility of major selection bias, the study cohort of 162 patients was compared to the 38 excluded patients with .9 months of follow-up data.
Clinical data. Data for the duration of systemic disease, the presence of antitopoisomerase antibodies, and the classification of disease as either limited cutaneous SSc or diffuse cutaneous SSc were obtained. Smoking status was defined as never, former (.1 cigarette/day for .1 year), or current smoking. Treatment was defined as a current therapeutic regimen of corticosteroids (prednisolone at a dosage of $1 mg/day) and/or immunosuppressant agents (cyclophosphamide, azathioprine, mycophenolate, or cyclosporine). Treatment status was subcategorized as either active treatment (treatment instituted within 3 months of presentation or continuation of preexisting treatment) or observation (no therapy at 3 months of follow-up). Transthoracic echocardiography and HRCT of the chest were performed as previously reported (21) . The presence of pulmonary hypertension (PH) on echocardiography was defined as a pulmonary arterial systolic pressure of $40 mm Hg (22) . The United Kingdom Raynaud's and Scleroderma Association severity staging system, which integrates the variables of disease extent identified on HRCT and FVC levels, was used to subclassify the level of disease severity at presentation as either limited lung fibrosis or extensive lung fibrosis (3) .
Pulmonary function data. Standard PFTs (with results expressed as absolute values and as the percent predicted) were performed (23) , including determination of the 1) FVC levels, 2) gas transfer (diffusing capacity for carbon monoxide [DLCO]) levels, 3) gas transfer coefficient (carbon monoxide transfer coefficient [KCO]) levels, and 4) FVC:DLCO ratio. PFT measurements were obtained at baseline (i.e., at presentation to our unit), at 12 months (range 9-18 months) from baseline, and at 24 months (range 18-30 months) from baseline. PFT trends were analyzed as continuous change and as categorical change in separate models. PFT change was computed as the percent change relative to the absolute values at baseline, i.e., a 10% relative decline in the FVC equates to an absolute change in the FVC level from a baseline value of 2.0 liters to a follow-up value of 1.8 liters.
Categorical PFT trends at 12 months were defined as 1) decline in the FVC of $10%, 2) decline in the FVC of $15%, 3) decline in the DLCO of $15%, 4) decline in the FVC of $10% or decline in the DLCO of $15%, 5) decline in the FVC of $10% and decline in the DLCO of $15%, 6) decline in the KCO of $10%, 7) rise in the FVC:DLCO ratio of $10%, 8) rise in the FVC:DLCO ratio of $15%, and 9) rise in the FVC:DLCO ratio of $20%. Trends examined at 24 months consisted of 1) decline in the FVC of $10%, 2) decline in the DLCO of $15%, 3) decline in the KCO of $10%, 4) rise in the FVC:DLCO ratio of $10%, 5) rise in the FVC:DLCO ratio of $15%, and 6) rise in the FVC:DLCO ratio of $20%. In addition, composite categorical decline (CCD), a measure that has been utilized previously in an IPF trial (24) , was defined as either a decline in the FVC of $10% or a decline in the FVC of 5-9% in combination with a decline in the DLCO of $15%.
Statistical analysis. Analyses were performed using Stata software (Computing Resource Centre). Data are expressed as the mean 6 SD or median (range), depending on distribution. Groups were compared using Student's t-test, Wilcoxon's rank sum test, chi-square test, and Fisher's exact test, as appropriate. P values less than 0.05 were considered significant. The 15-year survival rate was examined using univariate proportional hazards analysis against baseline variables, against change in individual PFT results at 12 months, and against change in individual PFT results at 24 months. Information on survival at 15 years (vital status, date of death), obtained from patient records and from general practitioners, was available for all but 1 patient (censored at 108 months).
Stepwise multivariate models were constructed in order to identify the determinants of mortality after 12 months of follow-up and, separately, after 24 months of follow-up. In both models, key covariates included stage of ILD at baseline (limited versus extensive lung fibrosis), severity of pulmonary vascular limitation at baseline (percent predicted KCO), progression of ILD (categorical decline in the FVC), and progression of pulmonary vascular limitation (categorical decline in the KCO). Other covariates consisted of age, sex, treatment status (active treatment versus observation), smoking status, and the presence or absence of PH, as judged by echocardiography.
RESULTS
Baseline PFT data and their prognostic significance. Demographic data and baseline PFT findings are summarized in Table 1 . The cohort was characterized by a predominance of female patients, and by the presence of limited lung fibrosis in 70% of patients. There were 84 deaths (52% of patients) during a median follow-up of 155 months. There were no significant differences between the study cohort (n 5 162) and excluded patients (n 5 38) with regard to sex (P 5 0.33), smoking status (P 5 0.57), baseline PFT results (FVC levels [P 5 0.77], DLCO levels Findings at 12 months. PFT trends at 12 months and their prognostic significance. The prognostic significance of 12-month trends in the FVC and DLCO are shown in Table 2 . Only continuous FVC change in patients with extensive lung fibrosis was predictive of outcome. In contrast, in all analyses, categorical decline in the FVC and/or DLCO was predictive of mortality both in the whole cohort and in patients with extensive lung fibrosis, although these measures were never predictive of mortality in patients with limited lung fibrosis (see Figures 1A-C for the survival data at the FVC 10% threshold). Categorical decline was most strongly predictive of mortality in the whole cohort when quantified as either the CCD or the decline in both FVC and DLCO (both found to be a less sensitive measure of decline than the CCD), and this finding was replicated in patients with extensive lung fibrosis ( Figures  2A-C) .
Decline in the KCO (analyzed as continuous change and as a decline of $10% in separate models) and increases in the FVC:DLCO ratio (analyzed as continuous change and as rises of $10%, $15%, or $20% in separate models) were not predictive of mortality in the whole cohort, nor were they predictive in the subgroups of either limited lung fibrosis or extensive lung fibrosis (data not shown). Moreover, when the analysis was confined to patients in the active treatment subgroup (n 5 35), the prognostic value of individual variables was unchanged in those with extensive lung fibrosis (continuous change in the FVC, P 5 0.03; $10% decline in the FVC, P , 0.01; $15% decline in the FVC, P , 0.05; $10% decline in the FVC and $15% decline in the DLCO, P 5 0.04; CCD, P , 0.001).
Multivariate analysis at 12 months. In stepwise proportional hazards analysis of the whole cohort at 12 months, the independent determinants of mortality were age (HR 1.03, 95% CI 1.01-1.05; P , 0.005), baseline stage of disease (HR 2.30, 95% CI 1.43-3.70; P , 0.001), baseline KCO (HR 0.98, 95% CI 0.96-0.99; P , 0.005), CCD (HR 2.25, 95% CI 1.39-3.63; P , 0.001), and presence of PH (HR 2.05, 95% CI 1.07-3.91; P 5 0.03).
Covariates discarded from the model consisted of sex, treatment status (active treatment versus observation), smoking status, and decline in the KCO of $10%. The duration of systemic disease was also discarded from the model (reanalyzed in 149 patients with reliable information).
Findings at 24 months. PFT trends at 24 months and their prognostic significance. As shown in Table 3 and Figures 3A-C , prognostically significant PFT trends in the whole cohort consisted of change in the DLCO (categorical decline), change in the KCO (continuous change and categorical decline), and change in the FVC:DLCO ratio (categorical increase in the ratio at the 15% and 20% thresholds). Changes in the FVC (continuous change and categorical decline [data not shown]) and the CCD had no prognostic value. Prognostically significant trends in patient severity subgroups were confined to categorical changes in the KCO and the FVC:DLCO ratio in those with limited lung fibrosis, and change in the CCD in those with extensive lung fibrosis.
A categorical decline in the DLCO of $15% was associated with greater concurrent decline in the FVC than was observed in the remaining patients (mean 6 SD change in the FVC 213.3 6 12.6% versus 11.4 6 20.4%; P , 0.0005). In contrast, concurrent FVC trends were virtually identical in patients with and those without a categorical decline in the KCO of $10%.
Analyses were repeated separately in the active treatment subgroup (n 5 66) and observation subgroup (n 5 74). A categorical decline in the DLCO of $15% was the only variable to have prognostic significance both in the active treatment subgroup (HR 2.06, 95% CI 1.03-4.12; P 5 0.04) and the observation subgroup (HR 2.07, 95% CI 1.05-4.08; P 5 0.04). A categorical decline in the KCO of $10% remained significant in the observation subgroup (P , 0.005) but was only marginally significant in the active treatment subgroup (P 5 0.11).
Multivariate analysis at 24 months. In stepwise proportional hazards analysis of the whole cohort at 24 months, the independent determinants of mortality were age (HR 1.05, 95% CI 1.03-1.07; P , 0.0005), baseline stage of disease (HR 2.76, 95% CI 1.66-4.80; P , 0.0005), baseline KCO (HR 0.97, 95% CI 0.95-0.98; P , 0.0005), decline in the KCO of $10% (HR 2.46, 95% CI 1.42-4.21; P 5 0.001), and decline in the CCD (HR 2.25, 95% CI 1.36-3.72; P , 0.005). Covariates discarded from the model were sex, treatment status, smoking status, and presence of PH. The duration of systemic disease was also discarded from the model (reanalyzed in 142 patients with reliable information). 
DISCUSSION
In this cohort of patients with SSc-associated ILD followed up for more than 15 years, PFT trends at 1 and 2 years were predictive of intermediate-term to long-term mortality. At 1 year, changes in the FVC provided the most accurate prognostic information, with the optimal expression of FVC change consisting of either a $10% decline in the FVC from baseline or a marginal (i.e., 5-9%) decline in the FVC in association with a definite (i.e., $15%) decline in the DLCO. The prognostic value of PFT trends in the whole cohort was entirely ascribable to disease progression in patients with extensive lung fibrosis. At 2 years, serial gas transfer trends predicted survival much more accurately than did FVC trends. The fact that trends in the DLCO and CCD at 2 years were independently predictive of mortality after adjustment for baseline severity variables underlines the importance of integrating baseline data and serial PFT trends in prognostic evaluation.
These findings support the view that the same broad approach to routine clinical monitoring is appropriate in patients with SSc-associated ILD as it is in those with IPF. In the 2011 international guidelines for the diagnosis and management of IPF (16), the importance of monitoring both the FVC and the DLCO was emphasized. In the current cohort, categorical decline in both variables at 1 year, both in isolation and in combination, were predictive of an increased long-term mortality rate.
The fact that gas transfer trends at 2 years had much greater prognostic significance than FVC trends may seem surprising, but this observation is consistent with the prognostic value of 3-year gas transfer trends observed in a previous, smaller cohort of patients with SScassociated ILD (25) . One possible explanation is that progression of SSc-associated ILD at 2 years may carry a greater threat to life expectancy when it has an impact on the pulmonary vasculature. However, a decline in gas transfer measurements did not always reflect progression of ILD. Specifically, decline in the DLCO at 2 years was associated with significantly greater decline in the FVC, whereas decline in the KCO (also predictive of mortality) was not linked to greater decline in the FVC. From these data, it can be concluded that the linkage between DLCO trends and mortality is likely a reflection of both progression of ILD and progression of pulmonary vasculopathy not ascribable to ILD.
The immediate implication is that DLCO decline in individual patients should be interpreted by also taking into consideration the concurrent changes in FVC. Importantly, a multivariate analysis of baseline data and PFT trends at 2 years against subsequent survival established that baseline and serial variables relevant to both ILD (i.e., baseline disease stage and CCD) and pulmonary vascular disease (i.e., baseline KCO and serial KCO) were all independently predictive of mortality, underlining the * Pulmonary function test (PFT) trends are expressed as continuous change or as categorical change at the predefined thresholds. Prognostic significance of the PFT variables in relation to risk of mortality is expressed as the hazard ratio (HR) with 95% confidence interval (95% CI). DLCO 5 diffusing capacity for carbon monoxide; KCO 5 carbon monoxide transfer coefficient; FVC 5 forced vital capacity; CCD 5 composite categorical decline. † Prevalence of change was calculated on the total group numbers, except that in patients with extensive lung fibrosis, the total was 39 patients for all calculations.
PULMONARY FUNCTION TRENDS IN SSc-ASSOCIATED ILDimportance of continuing to monitor both the FVC and the DLCO in the longer term, regardless of whether the disease has stabilized in the shorter term. The findings in the present study support a policy of cohort enrichment (i.e., selective recruitment of patients with SSc-associated ILD who have extensive disease). The growing consensus that patients with SSc-associated ILD who have mild lung involvement should not be recruited in treatment trials is based on the low prevalence of disease progression observed in these patients in a trial of oral cyclophosphamide for the treatment of sclerodermaassociated lung disease (26) , as was also observed in the present cohort, although in our earlier study, it was reported only as an integrated statement of "progressionfree survival" and not analyzed for individual variables (3).
The current findings present additional support for the idea of cohort enrichment for extensive lung fibrosis in clinical trial recruitment. Serial FVC trends (irrespective of the method of quantification) had no long-term prognostic value in patients with limited lung fibrosis, and therefore they lack credibility as clinically relevant end points in this patient subgroup. While the low prevalence of disease progression in limited lung fibrosis was a contributing factor, the absence of marginally significant relationships between disease progression and mortality in patients with limited lung fibrosis suggest that factors other than underpowering are likely to be at play. One possible explanation is that when lung fibrosis is limited, disease progression is more likely to be self-limited, as opposed to that in extensive disease, and therefore, short-term disease progression is less predictive of longer-term disease behavior than that in extensive lung fibrosis (in which, by definition, there is a "track record" of repeated disease progression). It is also possible that in limited SSc-associated ILD, antiinflammatory therapies (whether given for pulmonary indications or for systemic indications) are more efficacious in stabilizing disease and, thus, more likely to confound linkages between short-term disease progression and long-term outcome.
Equally important with regard to study design was the observation that FVC change had no prognostic significance when quantified as a continuous variable. This observation contrasts with the findings in IPF studies (6) and calls into question the idea that we may extrapolate the data from current practice in IPF trials, in which the most frequent primary end point is continuous change in FVC. The less progressive nature of SSc-associated ILD, as compared to IPF, may be the most important consideration. It is generally accepted that in IPF, disease progression is the rule, although the rate of progression is variable and decline is interspersed with periods of stability. In contrast, long-term stabilization is seen in a significant proportion of patients with SSc-associated ILD, even in extensive lung fibrosis, and in other patients, progression is much more insidious than has been typically observed in patients with IPF. As a consequence, it appears likely that, when compared to patients with IPF, a greater proportion of continuous FVC change at 1 year in patients with SSc-associated ILD is ascribable to measurement variation, whereas major FVC change captured by threshold analyses is much less likely to be spurious.
The mode of expression of categorical change in FVC is a contentious area of research. In clinical cohorts, a relative change of 10% from baseline has been shown to be predictive of mortality in the majority of IPF studies (6, 8, (11) (12) (13) 15 ). An absolute change in the FVC of 10% of the predicted normal value also is a predictor of mortality (7, 9, 14) , but this larger amplitude of change is less prevalent than relative change in a given time period (27) . In the current study, mortality was less strongly linked to a $10% decline in the FVC than it was to either a $15% decline in the FVC or both a $10% change in the FVC and a $15% change in the DLCO. However, the low prevalence of these alternative expressions of categorical decline may preclude their use as trial end points. Our findings suggest that when the prevalence and the prognostic significance of decline are both taken into account, the optimal definition of categorical decline in FVC for trial purposes may consist of either a $10% decline in the FVC or a 5-9% marginal decline in the FVC in association with a $15% decline in the DLCO. The use of DLCO trend data to indicate that marginal FVC change is likely to be clinically significant in individual patients (i.e., may represent an understatement of FVC change due to measurement variation in those cases) justifies amalgamation of trends in this way (28) and was the basis for an integrated FVC and DLCO end point in a recent trial assessing patients with IPF (24) . Our findings support a recent expert group recommendation for use of this end point in future trials of patients with SSc-associated ILD (29) .
Our findings suggest that with regard to monitoring, serial change in the FVC:DLCO ratio is inferior to KCO trends. In recent years, the FVC:DLCO ratio has been advocated as a marker of pulmonary vasculopathy in SSc (30) (31) (32) . However, the growth in use of this index can only be viewed as surprising. The KCO gas transfer coefficient (also known as the DLCO/alveolar volume [VA]) has been used for many decades to quantify uptake in carbon monoxide per unit of VA. Reduced KCO levels have an inverse correlation with the FVC:DLCO ratio, and both variables quantify reductions in the DLCO that are disproportionate to lung volumes. However, the KCO has the critically important advantage of the measurement variability of a single variable (measured KCO is used in combination with measured VA to compute the DLCO). In contrast, the FVC:DLCO ratio has the measurement variability of 3 variables (the FVC, VA, and KCO). Substantially greater measurement variability is likely to explain the fact that a very large (20%) rise in the FVC:DLCO ratio is required to provide the same prognostic guidance as a 10% decline in the KCO.
It should be stressed that in all prognostic evaluations of SSc-associated ILD patient cohorts, there are important but unavoidable confounding factors. There is no current method of controlling definitively for treatment status, as this often changes radically during both shortterm and long-term follow-up. We adopted a simplified approach of adjustment for treatment, as in previous work (3), in which we categorized patients as being in either the active treatment subgroup or the observation subgroup, based on treatment decisions at presentation and during the first 3 months of follow-up. Taking this dichotomy into account had no influence on our findings when included in multivariate modeling, but this does not alter the fact that linkages between pulmonary function change and mortality might have been much stronger had a robust method of adjusting for treatment effects been possible. Similarly, a reliable means of distinguishing between respiratory and nonrespiratory mortality might conceivably have strengthened our findings, but in common with previous investigators in this field, we viewed this distinction as highly unsafe, especially given the fact that very few deaths occurred at our institution.
The fact that PH did not emerge as a major prognostic determinant in the current cohort is likely to reflect the use of echocardiography to identify PH at baseline. During the time period of our study, no routine protocol to perform right heart catheterization was in place, in part because targeted therapies for PH were not routinely prescribed. The inaccuracy of echocardiography in identifying PH may explain the prognostic value of the KCO in multivariate analysis, as a second marker of PH.
In summary, we have examined relationships between short-term pulmonary function trends and longterm outcome in ILD associated with SSc. Disease severity at baseline and subsequent pulmonary function trends were independent prognostic determinants. At 1 year, categorical FVC trends provide the most accurate prognostic information, especially when integrated with DLCO trends. At 2 years, changes in gas transfer are more informative, with KCO trends more accurate prognostically than rises in the FVC:DLCO ratio.
